Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial코로나19의 바이오마커, 호흡기 중재 및 의료 서비스에 대한 몰누피라비르의 효과 : 무작위, 위약 대조 시험Randomized Controlled Trial Published on 2022-08-012022-09-11 Journal: Annals of internal medicine [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, [키워드] 95% CI Analysis assigned baseline benefit C-reactive protein C-reactive protein (CRP Care change clinical benefit clinically Concentration COVID-19 CRP death discharge discharged double-blind Effect evaluated faster Hospitalization Hospitalized identify immunized improvement Improvements Inc Invasive mechanical ventilation less LLC median medical service medical services Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 molnupiravir Older oxygen oxygen saturation participant performed Phase 3 Placebo placebo-controlled placebo-treated participant placebo-treated participants potential clinical benefit progression randomization Randomized Randomly receiving reduction in Relative risk respiratory respiratory intervention respiratory interventions risk risk factor Risk factors risk reduction SARS-CoV-2 secondary service severe disease Sharp subsidiary therapy Trial [DOI] 10.7326/M22-0729 PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy and safety of molnupiravir for COVID-19 patients코로나19 환자에 대한 몰누피라비르의 효능 및 안전성Article Published on 2022-08-012022-09-11 Journal: European journal of internal medicine [Category] 치료제, [키워드] Abstract COVID-19 COVID-19 patient EIDD-2801 Meta-analysis MK-4482 molnupiravir SARS-CoV-2 [DOI] 10.1016/j.ejim.2022.05.024 PMC 바로가기 [Article Type] Article
P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective studyConference abstract Published on 2022-08-012022-10-05 Journal: Clinical lymphoma, myeloma & leukemia [Category] 치료제, [키워드] Antiviral effective molnupiravir Multiple myeloma oral Patient Prospective Study [DOI] 10.1016/S2152-2650(22)00491-8 [Article Type] Conference abstract
Nudix hydrolase 18 catalyzes the hydrolysis of active triphosphate metabolites of the antivirals remdesivir, ribavirin, and molnupiravirArticle Published on 2022-08-012022-11-15 Journal: The Journal of Biological Chemistry [Category] COVID19(2023년), SARS, 치료제, [키워드] Antiviral antiviral efficacy catalyzed cells cellular Concentration decrease demonstrated Efficiency endogenous enzyme expressed form hydrolase hydrolysis hydrolyzed limit metabolite molnupiravir notable nucleoside analog nucleotide nucleotide hydrolysis. NUDIX hydrolase NUDT18 occur Remdesivir respiratory epithelial cells ribavirin SARS-CoV-2 SARS-CoV-2 replication tested was determined [DOI] 10.1016/j.jbc.2022.102169 PMC 바로가기
Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approachSARS-CoV-2 감염에 대한 경구 항바이러스제의 가용성 및 윤리적 처방 접근의 요구 사항Review Published on 2022-08-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] Fulltext, SARS, 변종, 치료제, [키워드] Antiviral antivirals approach authorisation complexity condition conducted country COVID-19 draft drug Effectiveness Efficacy FIVE health system health systems hierarchy high risk indicated Medicine Mild-to-moderate molnupiravir national health authorities national health authority Nirmatrelvir non-hospitalised Omicron variant Patient patients with COVID-19 placebo-controlled Policy predicted Randomised trial Ritonavir SARS-CoV-2 SARS-COV-2 infection scoring system severe COVID-19 supported symptom onset Transparency treat USA [DOI] 10.1016/S1473-3099(22)00119-0 PMC 바로가기 [Article Type] Review
Outpatient treatment options to address the SARS-CoV-2 variant OmicronArticle Published on 2022-08-012023-07-09 Journal: Expert review of anti-infective therapy [Category] COVID19(2023년), [키워드] bebtelovimab COVID-19 molnupiravir Nirmatrelvir Outpatient [DOI] 10.1080/14787210.2022.2077191
Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge오미크론 서지(Omicron Surge)를 포함한 고형 장기 이식 수혜자를 위한 COVID-19 치료제에 대한 업데이트Review Published on 2022-08-012022-09-12 Journal: Transplantation [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] addition Anti-inflammatory therapy change Clinical outcome clinical trial consequence convalescent plasma COVID COVID-19 deaths drug early treatment Hospitalization Including Infection Major molnupiravir monoclonal antibody occurred omicron outcome prevented Prophylaxis recipient Remdesivir Research SARS-CoV-2 secondary infections Solid solid organ transplant Symptoms Therapeutics Therapies therapy Transplant Treatment utility virus-specific T-cell [DOI] 10.1097/TP.0000000000004200 PMC 바로가기 [Article Type] Review
SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster modelSARS-CoV-2 VOC 유형 및 생물학적 성별은 중증 COVID-19 드워프 햄스터 모델에서 몰누피라비르 효능에 영향을 미칩니다Article Published on 2022-07-292022-09-11 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 임상, 치료기술, 치료법, 치료제, [키워드] Affect Antiviral benefit Cell disease effect size Efficacy evaluate females ferret ferrets hamster highest Human airway epithelium IMPROVE in vivo Infection inhibited lung Lung injury magnitude males management molnupiravir omicron oral organoids pathogenicity potency prevented reduced reduction in SARS-CoV-2 SARS-CoV-2 variants severe COVID-19 Sex survived Transmission Treatment effect size Trial triggered variants of concern virus load VoC [DOI] 10.1038/s41467-022-32045-1 PMC 바로가기 [Article Type] Article
Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis중증이 아닌 COVID-19에 대한 항바이러스제 치료: 체계적인 검토 및 네트워크 메타 분석Meta-Analysis Published on 2022-07-252022-09-11 Journal: CMAJ : Canadian Medical Association journal = jour [Category] COVID19(2023년), meta-analysis, SARS, 변종, 치료제, [키워드] 95% CI 95% confidence interval Admission Adult patients antiviral drug antiviral drugs antiviral treatments approach assessment certainty certainty of evidence conducted COVID-19 database death development drug effective Effectiveness Evidence Hospital admission Hospital admissions moderate molnupiravir MOST Network meta-analysis Nirmatrelvir no effect omicron Omicron variant Patient patients patients with COVID-19 performed Placebo randomized trial randomized trials reduce reduced risk reducing Remdesivir risk Risk of bias risk of death Ritonavir searched standard care systematic review tested Treatment Trial trials variants [DOI] 10.1503/cmaj.220471 PMC 바로가기 [Article Type] Meta-Analysis
Developing New Treatments for COVID-19 through Dual-Action Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling이중 작용 항바이러스/항염 소분자 및 생리학적 기반 약동학 모델링을 통한 COVID-19에 대한 새로운 치료법 개발Review Published on 2022-07-202022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] (dexamethasone Anti-inflammatory Anti-SARS-CoV-2 Activity Antiviral antiviral agent Antiviral agents approach Baricitinib biochemical pathway Biochemical pathways characterization COVID-19 COVID-19 pandemic Critical Cytopathic effect develop Developing Dexamethasone drug target dual dual action early treatment effective Efficacy and safety health system health systems High-risk patients identify in silico in vitro in vivo model Infection inflammatory cascade inhibitor inhibitors mechanism Mild mild to moderate Mild to moderate COVID-19 modeling Moderate COVID-19 molecular docking molecule molnupiravir monoclonal antibodies multidisciplinary approach New Nirmatrelvir pandemic pathogen PBPK modeling pharmacological protocol Ritonavir therapeutic agent therapeutic agents threat Treatment treatment of COVID-19 Viral virus viruses [DOI] 10.3390/ijms23148006 PMC 바로가기 [Article Type] Review